UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________________________________________________
FORM 8-K
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) October 22, 2020
CANTEL MEDICAL CORP.
(Exact name of registrant as specified in its charter)
| | | | | | | | |
| Delaware | 001-31337 | 22-1760285 |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Identification Number) |
| | | | | | | | | | | | | | | | | | | | |
| 150 Clove Road | Little Falls | New Jersey | 07424 | | (973) | 890-7220 |
| (Address of principal executive offices) | | | (Zip code) | | (Registrant's telephone number, including area code) | |
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | |
| Common Stock | CMD | New York Stock Exchange |
| (Title of each class) | (Trading Symbol) | (Name of each exchange on which registered) |
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. o
Item 2.02 Results of Operations and Financial Condition.
On October 22, 2020, the Registrant issued a press release announcing preliminary, unaudited estimated revenue results for the first quarter ended October 31, 2021. A copy of the press release is included with this Report as Exhibit 99.1.
The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements, Pro-Forma Financial Information and Exhibits.
(d) Exhibit 99.1 Press release of Registrant dated October 22, 2020.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | | | | | | |
| | CANTEL MEDICAL CORP. | |
| | | |
| | | |
| | By: | /s/ Shaun M. Blakeman |
| | | Shaun M. Blakeman |
| | | Chief Financial Officer |
| | | |
| October 22, 2020 | | |
